Isofol Medical AB (publ)
OM:ISOFOL Stok Raporu
Piyasa değeri: SEK 508.8m
Isofol Medical Yönetim
Yönetim kriter kontrolleri 0/4 Isofol Medical CEO'su Petter Lindqvist, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.04% doğrudan sahiptir ve bu hisselerin değeri SEK 205.80K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 0.8 yıldır.
Anahtar bilgiler
Petter Lindqvist
İcra Kurulu Başkanı
CEO maaş yüzdesi n/a CEO görev süresi less than a year CEO sahipliği 0.04% Yönetim ortalama görev süresi less than a year Yönetim Kurulu ortalama görev süresi less than a year
Son yönetim güncellemeleri
Isofol Medical AB (Publ) Announces That Magnus Hurst, Chief Financial Officer to Leave the Company, Effective from September 2, 2024 Jun 13
Isofol Medical AB (publ), Annual General Meeting, May 08, 2024 Feb 08 Isofol Medical AB (publ) Announces Chief Financial Officer Changes Jan 11
Isofol Medical AB (publ) Announces CEO Changes Jan 09
Isofol Medical AB (Publ) Appoints Jan-Eric Österlund as Member of the Board Dec 13
Isofol Medical AB (publ) Announces Appointment of Nomination Committee Members Nov 09
Tüm güncellemeleri göster Isofol Medical AB (publ) to Report Q3, 2025 Results on Nov 12, 2025
Isofol Medical AB (Publ) Strengthens the Outlook for Further Extending the Patent Protection of Its Drug Candidate Arfolitixorin Sep 17
Isofol Medical AB (Publ) Announces New Preclinical Data Supporting the Previously Communicated Clinical Development Plan for Arfolitixorin Jul 17
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow Jul 12
Isofol Medical AB (Publ) Announces That Magnus Hurst, Chief Financial Officer to Leave the Company, Effective from September 2, 2024 Jun 13
New major risk - Share price stability Mar 19
Full year 2023 earnings released: kr0.23 loss per share (vs kr0.99 loss in FY 2022) Feb 22
Isofol Medical AB (publ), Annual General Meeting, May 08, 2024 Feb 08 Isofol Medical AB (publ) Announces Chief Financial Officer Changes Jan 11
Isofol Medical AB (publ) Announces CEO Changes Jan 09 Isofol Medical AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025
Isofol Medical AB (Publ) Presents Additional Results from Laboratory Tests with Arfolitixorin Showing Supplementary Effects Dec 29
Isofol Medical AB (Publ) Appoints Jan-Eric Österlund as Member of the Board Dec 13
New major risk - Market cap size Dec 08
Isofol Receives the First Results from Laboratory Tests of Arfolitixorin Dec 08
Third quarter 2023 earnings released: kr0.04 loss per share (vs kr0.20 loss in 3Q 2022) Nov 12
Isofol Medical AB (publ) Announces Appointment of Nomination Committee Members Nov 09
New major risk - Revenue and earnings growth Oct 10
Isofol Medical AB (publ) Announces Results from the Modelle 001 Study Oct 06
Second quarter 2023 earnings released: kr0.05 loss per share (vs kr0.34 loss in 2Q 2022) Aug 23
Isofol Medical AB (publ) Presents Conclusions from the In-Depth Analysis of the AGENT Study Jul 06
New major risk - Share price stability Jul 05
High number of new and inexperienced directors Jul 02 Isofol Medical AB (publ) Appoints Roger Tell as Acting CEO
Isofol Medical AB (Publ) Announces Resignation of Thomas Andersson as Chief Executive Officer Jun 22
Isofol Medical AB (publ) Announces Board Changes Jun 08
High number of new and inexperienced directors Jun 01
First quarter 2023 earnings released: kr0.09 loss per share (vs kr0.32 loss in 1Q 2022) May 08
Isofol Medical AB (publ) Approves Election of Annika Freij as Member of Board of Directors May 04
Full year 2022 earnings released: kr0.99 loss per share (vs kr1.59 loss in FY 2021) Feb 23
Isofol Medical AB (Publ) Approves Not to Pay Extra Dividend Feb 14
Consensus EPS estimates fall by 15% Feb 03
No longer forecast to breakeven Jan 29
Isofol Medical AB (publ) Proposes Dividend, Payable on 20 February 2023 Jan 20
No longer forecast to breakeven Dec 14
Isofol Medical AB (publ) Announces Resignation of Ulf Jungnelius as CEO, Effective on June 1, 2023 Nov 29
Isofol Medical AB (Publ) Announces Final Data from the Agent Study Confirms Topline Results Nov 25
Consensus forecasts updated Nov 18
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13
Consensus forecasts updated Nov 12 Isofol Medical AB (publ), Annual General Meeting, May 03, 2023
Isofol Medical AB (publ) Appoints Nomination Committee Ahead of the Annual General Meeting 2023 Nov 04
Isofol Medical Reports Data from the Agent Study Sep 08
Isofol Medical AB (publ) Provides Update on AGENT Study Sep 01
Consensus revenue estimates fall by 40% Aug 30
Consensus forecasts updated Aug 17
Forecast breakeven date pushed back to 2024 Aug 16
Isofol Medical AB (publ) Announces Failure of Agent Phase III Trial Aug 06
Price target increased to kr25.00 Aug 05
Isofol Medical AB (publ) Announces Topline Results of Phase III AGENT Study Aug 04
High number of new directors Jul 31
Forecast breakeven date pushed back to 2024 Jul 17
High number of new directors Jun 02
Isofol Medical AB (publ) Approves Board Changes May 20
Consensus forecasts updated May 19
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued May 18
Forecast to breakeven in 2023 Apr 27
High number of new directors Apr 27
Isofol Announces Start of Study Data Analysis of Phase III Agent Study in Advanced Metastatic Colorectal Cancer Apr 23
Consensus forecasts updated Mar 12
Forecast to breakeven in 2023 Mar 10
Consensus forecasts updated Mar 03
Forecast breakeven date pushed back to 2024 Mar 02
Full year 2021 earnings: EPS and revenues exceed analyst expectations Feb 25
Price target decreased to kr23.00 Dec 06
Consensus forecasts updated Dec 05
Isofol Medical AB (publ) Receives FDA Fast Track Designation for Arfolitixorin in Advanced Colorectal Cancer Nov 24
Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation Nov 09
Consensus forecasts updated Jul 15
Isofol Medical AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 400.156634 million. Jun 15
Consensus revenue estimates increase to kr23.8m May 21
Price target decreased to kr31.00 May 21
Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans? May 12
Isofol Completes Recruitment of Japanese Patients in the Global Phase III Agent Study May 06
Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL) Apr 08
Consensus forecasts updated Mar 24
Isofol Medical AB (Publ) Receives Recommendation from iDSMB to Complete the Global Phase III Agent Study for Market Registration as Planned with 440 Patients Mar 21
Analysts update estimates Mar 05
Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment Mar 03
Revenue and earnings beat expectations Feb 27
Isofol Medical AB (Publ) to Present Gene Expression Results from the Completed Phase I/IIa ISO-CC-005 study Jan 16
New 90-day high: kr33.10 Jan 11
We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully Jan 10
New 90-day high: kr19.15 Dec 16
Isofol Medical AB (publ) Reaches 440 Patients in Global Phase III AGENT Study Dec 10
Analysts update estimates Nov 20
Isofol Medical AB (publ), Annual General Meeting, May 20, 2021 Nov 20
CEO less than a year
Görev süresi Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha ... Show more
Liderlik Ekibi İsim Pozisyon Görev süresi Tazminat Sahiplik Chief Executive Officer less than a year Veri yok 0.040% SEK 205.8k Chief Financial Officer less than a year Veri yok Veri yok Chief Medical Officer less than a year Veri yok Veri yok
Daha fazla göster 0.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim: ISOFOL 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri İsim Pozisyon Görev süresi Tazminat Sahiplik Independent Chairman less than a year SEK 996.00k 0.40% SEK 2.0m Independent Director less than a year Veri yok 0.0019% SEK 9.8k Independent Director less than a year SEK 29.00k 0.25% SEK 1.3m Independent Director less than a year SEK 271.00k Veri yok Independent Director less than a year Veri yok Veri yok
Daha fazla göster 0.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim Kurulu: ISOFOL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
